INTRODUCTION
Multiple myeloma (MM) is a relatively rare hematological malignancy that affects *1-9 in 100,000 individuals each year worldwide with a higher incidence in North America (7.1 in 100,000 per year) [1] . Although considerably prevalent in developed Western countries, prevalence statistics are substantially lower in developing countries, including Asian countries [2] . An epidemiological study in Taiwan reported an average incidence of 0.75 per 100,000 MM patients with a mortality rate of 0.59 per 100,000 deaths [3] .
This incurable disease, which has a median survival of 5 years, poses the major challenge of multiple relapse [4, 5] . The standard of care for MM includes alkylating agents, anthracyclines and corticosteroids with or without hematopoietic stem cell rescue, or high-dose therapy with hematopoietic stem cell rescue [6] .
Although this conventional approach offers adequate disease control, treatment benefit durability is limited and disease progression is almost inevitable. Over the last decade, the therapeutic approach for MM has evolved and the treatment paradigm has shifted to novel drugs that target different mechanistic pathways, such as immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (e.g., bortezomib) [1, [7] [8] [9] . These new agents have been extensively studied in the relapsed or refractory setting, demonstrating higher response rate (up to 50%) than the conventional therapies [10] [11] [12] . They are being used as successful salvage therapies (monotherapy or combination) in patients with relapsed MM [13, 14] .
With the changing therapeutic landscape for MM, wherein efforts are tailored to formulate the best possible treatment sequence, thalidomide, lenalidomide, and bortezomib are now being introduced as an inductive treatment strategy [15] . The use of thalidomide, lenalidomide, and bortezomib in newly diagnosed MM patients has been illustrated in a few studies, suggesting that early introduction of these drugs as front-line therapy may improve the therapeutic outcomes [16, 17] . The results of the VISTA (NCT00111319) studies confirm the therapeutic advantage of bortezomib use in combination with melphalan-prednisone in patients with newly diagnosed MM who are ineligible for high-dose therapy [18, 19] .
Bortezomib is the first proteasome inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed as well as relapsed MM [20] [21] [22] . It is also approved in Europe and several other countries (including China) for the treatment of MM [23, 24] .
Bortezomib exhibits a favorable safety profile and overall response rate of up to 67%, when used in combination with dexamethasone in patients with relapsed and refractory MM [17, 25, 26] . Moreover, due to its unique mechanism of action, bortezomib is associated with low incidences of thromboembolic complications, and may provide a better safety profile than immunomodulatory agents (thalidomide and lenalidomide) [27] .
Although the efficacy and safety of bortezomib is well established, validation of its benefits in patients of different ethnic backgrounds is warranted. This phase 4 observational study was designed to document the utilization, efficacy and safety of bortezomib in Chinese patients with relapse or refractory MM, with at least one prior chemotherapy regimen, in a real-world practice scenario.
METHODS

Study Population
Male and female Chinese patients aged C18 years, diagnosed with relapsed or refractory MM and having undergone at least one prior chemotherapy regimen were enrolled. All patients participating in the study had was administered for a maximum of 8 treatment cycles. The dose modification was allowed based on the treating physician's judgment (Table 1) .
Prospective observational data were collected at baseline and at the end of each treatment cycle up to 8 cycles. Subsequently, the patients were followed up every 12 weeks for up to 3 years (from the date of initiation of bortezomib treatment) to collect the survival and future disease progression data. All concomitant medications, except use of bortezomib, were allowed.
Assessments
Primary Analyses
Retrospective data of prior usage of bortezomib were analyzed to determine treatment sequence 
Exploratory Analyses
The extent of healthcare resource utilization (emergency room visits, inpatient hospital stays [and reasons for hospitalization], and days of each hospital stay) associated with bortezomib therapy was determined.
Statistical Methods
As this was an observational study, no formal sample size calculation was performed. The data were analyzed using SAS, version 9. 
RESULTS
Patient Demographics and Baseline Characteristics
Of the 517 patients enrolled in this study, 515
received the study drug. Data presented as n; median (range), unless otherwise specified. All enrolled analysis set included patients who were enrolled in the study SD standard deviation, WBC white blood cells n = 73) followed by disease remission (13.7%, n = 69) and AEs (10.7%, n = 54).
Discontinuations were unclear for 48 (9.5%) patients; whereas, other discontinuations were due to death (4%), loss to follow-up/noncompliance/voluntary withdrawal (4%), transplant (3.2%), no response/progression (3.2%), use of other chemotherapy (1.2%), others (1.0%) and hospital beds (0.2%).
Overall, the reasons for discontinuations of 176 (35.0%) patients who maintained bortezomib after 8 cycles were unknown.
Utilization of Bortezomib
A total of 248 (48.2%) enrolled patients used bortezomib as third-line treatment ( AE. The most frequently reported AE was thrombocytopenia (14.4%, n = 74) ( Table 5 ).
Most of the AEs (*35%) were grade 1 or 2 in severity, with few grade 3 (16.7%) or grade 4 (6.4%). Drug-related AEs occurred in 53.8% of patients. The incidence of serious adverse events (SAE) was low (6.4%); deaths and lung infections were reported in nine patients each. Thrombocytopenia as a SAE was reported by two patients.
The most commonly (C10% of patients) reported AEs of special interest (assessed as per WHO Common Toxicity Criteria) were infection (16.3%, n = 84), thrombocytopenia (14.8%, n = 76), diarrhea (14.0%, n = 72), peripheral sensory neuropathy (10.7%, n = 55), weakness (11.8%, n = 61), and paresthesia (10.7%, n = 55). The majority (55.2%, n = 284) of these AEs were Bgrade 2 in severity, with few grade 3 (15.0%, n = 77) or 4 (4.1%, n = 21) AEs.
Healthcare Utilization
In total, 148 (28.0%) of the enrolled patients did not require any hospital stay. Of the patients who were hospitalized, most (22.8%, n = 118) required only one stay (mean days [SD], 31.9
[55.6]). Of the 1,039 types of hospitalization, the most frequent was voluntary hospitalization (92.8%, n = 964), followed by emergency (6.1%, n = 63), acute (0.7%, n = 7), and unknown (including case report form unfilled) (0.5%, n = 5).
DISCUSSION
The therapeutic paradigm for MM has now shifted in light of the demonstrated therapeutic advantages of proteasome inhibitors and immunomodulators over conventional strategies [28, 29] . As a result, these drugs have emerged as a more feasible treatment option for patients with relapsed/refractory MM, particularly those ineligible for high-dose chemotherapy. Bortezomib is the first proteasome inhibitor approved for treatment Table 5 Adverse events in C5% of bortezomib-treated patients with relapsed/refractory multiple myeloma (safety analysis set) [NCT00048230]) [10] [11] [12] . The population enrolled in these global studies had baseline characteristics similar to the population of this study (age of *60 years and majority had Durie-Salmon staging of stage IIIa). When compared with the VOBS trial conducted in the Chinese population, the ORR ([70%) was similar to that noted in this study. Taken together, these studies highlight the difference in treatment sensitivity within populations belonging to diverse ethnic backgrounds (Caucasian and Asian) [31] . Of note, the treatment strategies employed for these two populations were not similar, which might have also contributed to the higher ORR observed in Chinese patients (VOBS trial) compared with Caucasian patients (Global trials). In the Caucasian population, bortezomib was initiated as monotherapy, and dexamethasone was introduced during the course of treatment only if required; while in the Chinese population, bortezomib was initiated as combination therapy in most patients. Of the evaluable patients in this study, the majority demonstrated PR. Although stable disease status was not achieved in most of the patients, those demonstrating disease progression were notably few. These findings were consistent with the APEX study [12] which supports the therapeutic advantage of bortezomib when introduced early as salvage treatment in the course of disease.
The median time to first response was notably shorter in this study (27 days) compared with results from studies in Caucasians (1.3-1.5 months) [10, 11] , but was consistent with an earlier study in Chinese population reporting median time to response of 33-38 days [31] . Further, the duration of response was longer in this population (*20 months) compared with Caucasians (12.7 months). A longer duration of response generally translates into improved treatment outcomes [12] . The disease progression rate in this study was minimal by day 30 and increased gradually as time progressed. Overall, this observational study in real-world setting demonstrates the utilization and feasibility of bortezomib, confirming its use in Chinese patients with relapse or refractory MM.
Further, no unexpected safety findings were observed in this Chinese population. The most common AEs (C10%) were decrease in platelet count, diarrhea, peripheral neuropathy, and hypoesthesia. Overall, bortezomib treatment was associated with manageable AEs and did not limit the continuity of therapy. The incidence of deaths, SAEs and AEs leading to discontinuation were overall low. The safety outcomes indicated that treatment with bortezomib produces a manageable toxicity profile in the Chinese population.
Limitations
One limitation of this study was the short follow-up period. A longer than 3-year followup period would help to better interpret the survival data. This corroborated with the VISTA study wherein the follow-up period was similar to our study, and no conclusive results were obtained with respect to OS. This study lacked any novel findings or any additional treatment benefits related to bortezomib. The treatment effects noted in the Chinese population were similar to the known therapeutic outcomes of bortezomib.
CONCLUSION
This study demonstrates that a bortezomibbased regimen was feasible in Chinese patients with relapse or refractory MM. Bortezomib was associated with good response rates, and a manageable safety profile consistent with previous studies and clinical experience. 
